Meditope Biosciences

Meditope is an R&D-stage antibody-drug conjugate (ADC) company dedicated to transforming cancer treatment through its proprietary conjugation technology enabling precision targeted delivery of cancer drugs and radiotherapies to the tumor. Meditope's innovative approach is protected by 21 international patents, ensuring exclusive rights to their groundbreaking methods. Its mission is to develop targeted therapies that offer new hope to patients battling cancer, initially those with multiple myeloma and followed by treatments for solid tumors.